Skyrizi Injection and Ustekinumab Intravenous Infusion
Determining the interaction of Skyrizi Injection and Ustekinumab Intravenous Infusion and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: The use of ustekinumab with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious bacterial, fungal, and viral infections have been observed during clinical trials with ustekinumab, and the risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (greater than 10 mg/day to 1 mg/kg/day, whichever is less, of prednisone or equivalent for more than 2 weeks), and long-term topical or inhaled corticosteroids. MANAGEMENT: Caution is advised if ustekinumab must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. References "Product Information. Stelara (ustekinumab)." Centocor Inc, Malvern, PA.
Professional:MONITOR: The use of ustekinumab with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious bacterial, fungal, and viral infections have been observed during clinical trials with ustekinumab, and the risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (greater than 10 mg/day to 1 mg/kg/day, whichever is less, of prednisone or equivalent for more than 2 weeks), and long-term topical or inhaled corticosteroids.
MANAGEMENT: Caution is advised if ustekinumab must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy.
- "Product Information. Stelara (ustekinumab)." Centocor Inc, Malvern, PA.
Generic Name: risankizumab
Brand name: Skyrizi
Synonyms: Risankizumab
Generic Name: ustekinumab
Brand name: Stelara, Stelara PFS
Synonyms: Ustekinumab
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Skyrizi Injection-Ustekinumab Subcutaneous
- Skyrizi Injection-Ustekinumab Subcutaneous Injection
- Skyrizi Injection-Ustell
- Skyrizi Injection-UTA
- Skyrizi Injection-UTA Capsules
- Skyrizi Injection-UTAC tablets
- Ustekinumab Intravenous Infusion-Skyrizi topical
- Ustekinumab Intravenous Infusion-Sleep Aid
- Ustekinumab Intravenous Infusion-Sleep Aid Tablets
- Ustekinumab Intravenous Infusion-Sleepinal
- Ustekinumab Intravenous Infusion-Slo-Niacin
- Ustekinumab Intravenous Infusion-Slow Fe